No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Niox Group said on Thursday that trading so far in 2026 had been in line with management expectations, as the medical device company reported an improved cash position and signed a long-term supply agreement for its FeNO sensors.
The AIM-traded asthma and COPD diagnostics specialist said cash stood at 22.3m at 30 April, up from 19.9m at the end of December, after payment of prior-year bonuses.
Niox said it had signed a 10-year exclusive supply agreement with its FeNO sensor supplier.
The agreement will allow the company to make targeted investments in the supplier to increase manufacturing capacity, strengthen long-term supply security and improve operational resilience as the business continues to scale globally.
The company said it remained focused on increasing penetration of FeNO testing and use of its Niox products in the US, rolling out the Niox Pro device, and continuing development of its Niox MyNO home-use device.
Regulatory approvals for Niox Pro are expected across various markets during 2026.
Niox said it would release a trading update for the six months ending 30 June in mid-July.
At 1238 BST, shares in Niox Group were down 2.78% at 59.89p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.